Dr. Choueiri on Existing Therapies for Kidney Cancer

Toni Choueiri, MD
Published: Tuesday, Apr 25, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Sunitinib (Sutent) remains a standard treatment in the first-line setting and is used as the control arm for multiple phase III trials. Pazopanib (Votrient) is a frontline standard therapy that is similar to sunitinib but may be better tolerated depending on the scheduling, states Choueiri.

There is a subgroup of patients that have certain mutations that are showing high response rates to everolimus (Afinitor), explains Choueiri.

SELECTED
LANGUAGE


Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Sunitinib (Sutent) remains a standard treatment in the first-line setting and is used as the control arm for multiple phase III trials. Pazopanib (Votrient) is a frontline standard therapy that is similar to sunitinib but may be better tolerated depending on the scheduling, states Choueiri.

There is a subgroup of patients that have certain mutations that are showing high response rates to everolimus (Afinitor), explains Choueiri.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x